ClinicalTrials.Veeva

Menu

Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models (TCI)

Sun Yat-sen University logo

Sun Yat-sen University

Status

Completed

Conditions

Healthy

Treatments

Procedure: Marsh Plasma TCI with high initial target
Procedure: Schnider Plasma TCI with high initial target

Study type

Interventional

Funder types

Other

Identifiers

NCT01759160
NSFCfengxiar1
Fengxia1 (Other Grant/Funding Number)

Details and patient eligibility

About

To compare the hemodynamic changes during anesthesia induction between Marsh and Schnider plasma TCI models. We put forward a hypothesis that, if one TCI model is associated with much more prominent vasodilation effect or cardiac depression, a more sharp decrease in mean arterial pressure, systemic vascular resistance , central venous return or stroke volume would be observed.

Full description

Current systems of propofol TCI are pre-programmed with the Marsh and Schnider pharmacokinetic models. Rate constants of Marsh are fixed, whereas compartment volumes and clearances are weight proportional. Schnider model has fixed values for VC, V3, k13, and k31, adjusts V2, k12, and k21 for age, and adjusts k10 according to total weight, lean body mass (LBM), and height. One major benefit of the Schnider model is that it adjusts doses and infusion rates according to patient age. This provides a strong argument for using the Schnider model in the elderly and unwell patients which may improve hemodynamic stability and safety.

However for the vast majority of young and middle age patients, whether Marsh or Schnider would be a better choice for hemodynamic stability remains unknown.

With marsh model, as VC is scaled to body weight, the amount of drug delivered is dependent of body weight. In the Schnider model, as VC at 4.27L is independent of body weight, VC in terms of ml/kg decreases as body weight increases. This and the influence of height and weight on clearance results in heavier patients receiving less propofol on a mg/kg basis whereas those with a lower lean body mass will initially receive about 30% less than delivered by Marsh, but after 30 min, the Schnider model delivers about 15% more. Besides, when Schnider model is used in the morbidly obese, the LBM equation can generate paradoxical values resulting in excessive increases in maintenance infusion rates. Nevertheless, the purpose of this study was to investigate the vast majority of Asian patients whose body weight were in normal range. Only patients with BMI between 18 and 29 were included to minimize the influential factor of body weight in TCI system.

To compare the hemodynamic changes during anesthesia induction between Marsh and Schnider plasma TCI models. We put forward a hypothesis that, if one TCI model is associated with much more prominent vasodilation effect or cardiac depression, a more sharp decrease in mean arterial pressure, systemic vascular resistance , central venous return or stroke volume would be observed.

Enrollment

60 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients between the ages of 18 years and 70 years
  • ASA physical status I and II
  • surgical procedures requiring general anesthesia with continuous CVP and arterial pressure monitoring.

Exclusion criteria

  • Patients younger than 16 y or older than 65 y
  • Body Mass Index (BMI) <18 or >30
  • emergency surgery
  • allergy to any of the drugs used
  • inability to communicate effectively
  • severe cardiovascular dysfunction
  • patient refusal and patients on long-term opioids or sedative medication.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 2 patient groups

Marsh
Active Comparator group
Description:
Marsh Plasma TCI with high initial target
Treatment:
Procedure: Marsh Plasma TCI with high initial target
Schnider
Active Comparator group
Description:
Schnider Plasma TCI with high initial target
Treatment:
Procedure: Schnider Plasma TCI with high initial target

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems